Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Allen & Hanburys Ltd
Stockley Park West, Uxbridge, Middlesex, UB11 1BT
Telephone: +44 (0)800 221 441
Fax: +44 (0)208 990 4328
Medical Information e-mail: customercontactuk@gsk.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 17/05/2012
SPC Serevent Accuhaler

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/05/2012 and displayed until Current
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 10 date of revision of the text
Updated on 07/01/2010 and displayed until 17/05/2012
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.9 - Overdose
  • Change to section 10 date of revision of the text
Updated on 20/08/2009 and displayed until 07/01/2010
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Updated on 24/09/2008 and displayed until 20/08/2009
Reasons for adding or updating:
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 10 date of revision of the text
Updated on 19/10/2007 and displayed until 24/09/2008
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Updated on 21/08/2006 and displayed until 19/10/2007
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 9 - Date of Renewal of Authorisation
  • Change to section 10 (date of (partial) revision of the text
Updated on 31/01/2005 and displayed until 21/08/2006
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 27/01/2005 and displayed until 31/01/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Pending awaiting re-submission
Updated on 22/03/2004 and displayed until 27/01/2005
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 22/03/2004 and displayed until 22/03/2004
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Pending awaiting re-submission
Updated on 18/03/2004 and displayed until 22/03/2004
Reasons for adding or updating:
  • Change to section 4.1 - Therapeutic Indications
  • Change to section 4.4 - Special Warnings and Precautions for Use
Updated on 06/11/2003 and displayed until 18/03/2004
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 4.3 - Contra-indications
  • Change to section 6.1 - List of Excipients
Updated on 29/09/2003 and displayed until 06/11/2003
Reasons for adding or updating:
  • Change to section 2 - qualitative and quantitative composition
  • Change to section 4.3 - Contra-indications
  • Change to section 6.1 - List of Excipients
Updated on 29/01/2003 and displayed until 29/09/2003
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 23/01/2003 and displayed until 29/01/2003
Reasons for adding or updating:
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 15/11/2002 and displayed until 23/01/2003
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 22/10/2002 and displayed until 15/11/2002
Reasons for adding or updating:
  • Change to section 9 - Date of Renewal of Authorisation
Updated on 16/08/2001 and displayed until 22/10/2002
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 22/03/2001 and displayed until 16/08/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 23/01/2001 and displayed until 22/03/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 18/10/2000 and displayed until 23/01/2001
Reasons for adding or updating:
  • No reasons supplied
Updated on 18/08/2000 and displayed until 18/10/2000
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 18/08/2000
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  salmeterol xinafoate